Target intelligence / Profile preview

Aldehyde oxidase 1 (AOX1)

Target
AOX1
Molecular classification
Enzyme, Oxidoreductase, Molybdo-flavoenzyme, Xanthine oxidase family protein
01

Overview

Aldehyde oxidase 1 (AOX1) is a cytosolic enzyme belonging to the xanthine oxidase family of molybdo-flavoenzymes. It forms homodimers and requires cofactors such as FAD, molybdenum (MoCo), and iron–sulfur clusters for activity. AOX1 catalyzes the oxidation of a broad range of endogenous and exogenous aldehydes—as well as aza-heterocyclic aromatic compounds—into carboxylic acids or hydroxylated products. This enzyme is one of the major phase I drug-metabolizing enzymes in human liver, contributing significantly to the clearance of various drugs and xenobiotics, and exhibits broad substrate specificity. Its interindividual enzymatic activity is highly variable due to genetic polymorphisms, leading to significant implications for drug pharmacokinetics, efficacy, and safety. AOX1 is also a notable target for drug interactions, with several clinically used drugs acting as its substrates or inhibitors, and is under consideration in drug development for predicting and mitigating adverse reactions and therapeutic failure.

Other names
Aldehyde oxidaseAOX1AOAOH1Azaheterocycle hydroxylase
02

Mechanism of action

Oxidative metabolism (oxidation of aldehydes and N-heterocycles in drugs and xenobiotics). Drug inhibition of AOX1 prevents metabolism of substrate drugs, increasing their bioavailability or leading to drug-drug interactions.

03

Biological functions

Phase I drug metabolismOxidation of aldehydes to carboxylic acidsHydroxylation of N-containing heterocyclesDetoxification of xenobioticsMetabolism of endogenous compounds
04

Disease associations

Other (pharmacogenomic variability and adverse drug reaction)Potential relevance in cancer, cardiovascular disease, and drug-related toxicity due to variable substrate metabolism
05

Safety considerations

High inter-individual variability due to genetic polymorphisms affecting drug clearanceUnpredictable drug-drug interactions (due to inhibition by other drugs/compounds)Limited metabolic pathways for drugs primarily metabolized by AOX1 can result in drug accumulation or toxicity if AOX1 is inhibited
06

Interacting drugs

Zaleplon

7 more in the full profile.

07

Biomarkers

AOX1 genetic polymorphisms/SNPs (altering enzyme activity, influencing drug metabolism rate and risk of adverse effects)

Beyond the preview

Go deeper on Aldehyde oxidase 1 (AOX1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aldehyde oxidase 1 (AOX1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call